iRadimed (NASDAQ:IRMD) Sees Unusually-High Trading Volume – Here’s Why

iRadimed Corporation (NASDAQ:IRMD) shares saw unusually-strong trading volume on Wednesday . Approximately 48,762 shares traded hands during mid-day trading, a decline of 45% from the previous session’s volume of 88,590 shares.The stock last traded at $88.7150 and had previously closed at $87.36.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on IRMD shares. Freedom Capital raised iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. Lake Street Capital reissued a “buy” rating and issued a $120.00 target price on shares of iRadimed in a research note on Wednesday, February 11th. Weiss Ratings raised shares of iRadimed from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, May 6th. Finally, Roth Mkm reissued a “buy” rating and set a $120.00 price objective on shares of iRadimed in a research report on Tuesday, February 10th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $120.00.

iRadimed Stock Performance

The stock has a 50-day moving average of $93.22 and a 200-day moving average of $94.91. The firm has a market cap of $1.14 billion, a price-to-earnings ratio of 48.68 and a beta of 0.90.

iRadimed (NASDAQ:IRMD) last issued its quarterly earnings results on Friday, May 1st. The medical equipment provider reported $0.49 EPS for the quarter, topping the consensus estimate of $0.46 by $0.03. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. The firm had revenue of $21.98 million for the quarter, compared to analysts’ expectations of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Sell-side analysts predict that iRadimed Corporation will post 1.52 EPS for the current fiscal year.

iRadimed Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 29th. Shareholders of record on Friday, May 15th will be given a dividend of $0.20 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $0.80 annualized dividend and a yield of 0.9%. iRadimed’s payout ratio is 43.72%.

Insider Activity at iRadimed

In other news, CEO Roger E. Susi sold 4,411 shares of the stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $83.92, for a total value of $370,171.12. Following the completion of the sale, the chief executive officer owned 2,180,000 shares of the company’s stock, valued at approximately $182,945,600. This represents a 0.20% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 60,000 shares of company stock valued at $5,661,603. Corporate insiders own 36.80% of the company’s stock.

Institutional Investors Weigh In On iRadimed

Several large investors have recently made changes to their positions in IRMD. T. Rowe Price Investment Management Inc. boosted its holdings in shares of iRadimed by 410.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock valued at $24,893,000 after buying an additional 205,783 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in iRadimed by 37.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 205,227 shares of the medical equipment provider’s stock worth $19,964,000 after purchasing an additional 55,426 shares during the period. Informed Momentum Co LLC bought a new position in iRadimed during the fourth quarter worth about $5,361,000. SG Americas Securities LLC grew its holdings in iRadimed by 88.6% during the fourth quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider’s stock worth $6,848,000 after purchasing an additional 33,072 shares during the period. Finally, Invesco Ltd. grew its holdings in iRadimed by 473.9% during the fourth quarter. Invesco Ltd. now owns 35,131 shares of the medical equipment provider’s stock worth $3,418,000 after purchasing an additional 29,010 shares during the period. Institutional investors and hedge funds own 92.34% of the company’s stock.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.